NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
National Institutes of Health Clinical Center (CC)
CellCentric Ltd.
Bristol-Myers Squibb
Zhejiang DTRM Biopharma
Calithera Biosciences, Inc